The neuroimaging group, consisting of Artinis and NIRx, leading in functional Near-Infrared Spectroscopy (fNIRS) solutions, has appointed Matthew Stork as Chief Executive Officer (CEO) and Maarten Jaspers as Finance Director....
Gilde Healthcare portfolio company Synox Therapeutics announces positive topline results from the Phase 3 TANGENT study
TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and...
13. April 2026
Gilde Healthcare appoints Matthew Stork as CEO and Maarten Jaspers as Finance Director of its neuroimaging technology group
The neuroimaging group, consisting of Artinis and NIRx, leading in functional Near-Infrared Spectroscopy (fNIRS) solutions, has appointed Matthew Stork as Chief Executive Officer (CEO) and Maarten Jaspers as Finance Director....
5. February 2026
Gilde Healthcare legt Climate Solutions Fonds auf und erzielt beim ersten Closing €250 Mio.
Mit Commitments internationaler Pensionsfonds, Banken, Fund-of-Funds, Endowments und Family Offices erreicht Gilde Healthcare ein erstes Closing in Höhe von €250 Mio Die Erweiterung um Climate Solutions baut auf Gilde Healthcare‘s...
18. February 2026
Gilde Healthcare portfolio company Synox Therapeutics announces positive topline results from the Phase 3 TANGENT study
TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and...
13. April 2026
Filter & Suche
Fondsstrategie :
Loading...
Das waren alles Artikel
fda6a61de4